BERKELEY & MORGAN HILL, Calif.--(BUSINESS WIRE)--XOMA Ltd. (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, and Aragen Bioscience, Inc., a provider of high-content preclinical research and development services, have entered into an agreement under which Aragen Bioscience will provide its clients access to XOMA’s proprietary Human Engineering™ technology for antibody humanization. Financial terms were not disclosed.
